This mid-cap multibagger company invests in cell and gene therapy company ImmunoACT!
This mid-cap multibagger company invests in cell and gene therapy company ImmunoACT!

This mid-cap multibagger company invests in cell and gene therapy company ImmunoACT!

Through this collaboration, the company aims to bring CAR-T therapy to Indian patients at an affordable price, filling the gap in access to this novel treatment option.

Siddharth Mane Article rating: 3.3

CAR-T therapy has shown significant success in the western world as a promising treatment option. However, this innovative technology is currently unavailable in India. Through this collaboration, the company aims to bring CAR-T therapy to Indian patients at an affordable price, filling the gap in access to this novel treatment option. 

From Rs 33 to Rs 394: This low PE Smallcap stock became multibagger in just 3 years!
From Rs 33 to Rs 394: This low PE Smallcap stock became multibagger in just 3 years!

From Rs 33 to Rs 394: This low PE Smallcap stock became multibagger in just 3 years!

The company reported a jump of 85 per cent in net profit to Rs 53.09 crore for Q3FY23 with improvement in margins.

Rohit Kale Article rating: 4.1

The stock has been a proven multibagger, having soared over 10 times since March 2020 low of Rs 33 to Rs 394 level in March 2023.

RSS

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR